Yet, "better drug discovery platforms" are perceived (at least by traditional pharma and clinical-stage biotech investors) as low-value, risky, and unserious. Pharma business development execs I've talked to have said that their companies don't license new screening tech at all!
-
-
The point is, the *general class* of improvements in screening platforms is where *all* the money is, and we need biotech companies structured end-to-end around predictive validity.
Show this thread -
(Well-known examples of improvements in predictive validity: drugs validated against human genetic targets are more likely to succeed in the clinic. Also, compounds discovered through phenotypic screening are a majority of successful first-in-class drugs.)
Show this thread -
"Optimize predictive validity" seems like really solid logic to me, and I expect it to seem common-sense to a lot of tech people and scientists, but I expect it sounds really "out there" to seasoned biotech execs, so I especially welcome critical feedback from them.
Show this thread
End of conversation
New conversation -
Loading seems to be taking a while.
Twitter may be over capacity or experiencing a momentary hiccup. Try again or visit Twitter Status for more information.